Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
Study Start Date
Estimated Primary Completion Date
Estimated Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men and women 18-55 years of age.
Primary DSM-IV diagnosis of adult ADHD confirmed by senior physician
Capable and willing to provide informed consent
Able to adhere to the treatment schedule, and withdrawal of ongoing pharmacotherapy for the treatment of ADHD prior to the beginning of the study treatment and during the study drug treatment.
Subjects must be able to read, hear, write and speak the local language.
Subject has signed a written informed consent to participate in the study.
Unstable or significant medical disorder.
Current (within 12 months of baseline) primary or secondary depression.
History of substance abuse or dependence within the past 6 months
Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features
Obsessive compulsive disorder
Post-traumatic stress disorder
Current generalized anxiety disorder
Presence of a personality disorder
Individuals with a significant other neurological disorder.
Use of any investigational drug within 4 weeks of the randomization visit
Known or suspected pregnancy
Women who are breast-feeding
Women of childbearing potential and not using a medically accepted form of contraception